AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

68.22USD
6 Jul 2015
Change (% chg)

-- (--)
Prev Close
$68.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,637,755
52-wk High
$70.76
52-wk Low
$51.40

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease; hepatitis C (HCV);... (more)

Overall

Beta: --
Market Cap(Mil.): $108,679.60
Shares Outstanding(Mil.): 1,593.08
Dividend: 0.51
Yield (%): 2.99

Financials

  ABBV.N Industry Sector
P/E (TTM): 60.65 35.83 39.20
EPS (TTM): 1.12 -- --
ROI: 9.54 17.03 16.19
ROE: 59.80 17.93 17.33
Search Stocks

AbbVie hepatitis C cocktail succeeds in late-stage study

- AbbVie Inc said on Wednesday that its hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with the compound ribavirin against the most common form of the disease, according to data from a late-stage study.

24 Jun 2015

UPDATE 1-AbbVie hepatitis C cocktail succeeds in late-stage study

June 24 - AbbVie Inc said on Wednesday that its hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with the compound ribavirin against the most common form of the disease, according to data from a late-stage study.

24 Jun 2015

AbbVie hepatitis C cocktail succeeds in late-stage study

June 24 - AbbVie Inc said on Wednesday that all patients in a late-stage study showed a sustained response to its cocktail of hepatitis C treatments, currently sold in the U.S. as Viekira Pak.

24 Jun 2015

Borrowers warned: Don't be fooled by high grade market resilience

NEW YORK, May 11 (IFR) - Apple, Shell and AbbVie blitzed the US bond market last week with a combined US$34bn of jumbo bond deals in just two days, bringing the week's tally to US$52bn, the fourth-largest of all time.

11 May 2015

Drugmaker AbbVie's profit beats estimates on strong Humira sales

- U.S. drugmaker AbbVie Inc reported better-than-expected quarterly profit and revenue, driven by strong sales of its arthritis drug, Humira.

23 Apr 2015

Drugmaker AbbVie profit rises on sales of Humira

April 23 - U.S. drugmaker AbbVie Inc reported a 4 percent rise in quarterly profit, driven by strong sales of its arthritis drug, Humira.

23 Apr 2015

Fresenius CEO says to sit out healthcare deal wave

MUNICH - German healthcare group Fresenius will lie in wait for an overheated healthcare deal market to cool down before making further larger acquisitions, its chief executive said.

22 Apr 2015

Top Mylan shareholders seek deal with Teva - sources

- Some of the top investors at Mylan NV , including Paulson & Co, are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc , according to people familiar with the matter.

22 Apr 2015

Top Mylan shareholders seek deal with Teva: sources

- Some of the top investors at Mylan NV, including Paulson & Co, are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc, according to people familiar with the matter.

22 Apr 2015

BRIEF-Ablynx starts first of phase IIb rheumatoid arthritis study with Abbvie

* Ablynx initiates the first of two phase IIb RA studies with its anti-il-6r nanobody, partnered with Abbvie

17 Mar 2015

Competitors

Earnings vs. Estimates

Search Stocks